Skip to main content
Clinical Trials/ACTRN12613000249752
ACTRN12613000249752
Completed
Phase 4

The Use of Intravitreal Injection of Triamcinolone Acetonide in Diabetic Patients to Reduce Diabetic Macular Edema

suez canal university hospital0 sites19 target enrollmentMarch 4, 2013

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Diabetic macular edema
Sponsor
suez canal university hospital
Enrollment
19
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 4, 2013
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
suez canal university hospital

Eligibility Criteria

Inclusion Criteria

  • The major eligibility criteria for the study eyes included the following: (1\) best\-corrected visual acuity letter score between 20/40 and 20/320; (2\) definite retinal thickening resulting from DME on clinical examination involving the center of the macula assessed to be the main cause of visual loss; (3\) retinal thickness measured with optical coherence tomography (OCT) of 250 micro m or more in the central subfield ;(4\) Grid laser treatment was done at least three months earlier.

Exclusion Criteria

  • Principal exclusion criteria included; (1\) prior treatment with intravitreal corticosteroids (at any time), peribulbar steroid injection within the prior 6 months, or pars plana vitrectomy (at any time); (2\) a history of glaucoma or steroid\-induced IOP elevation that required IOP\-lowering treatment; (3\) average intraocular pressure of 23 mm Hg or more after three preinjection evaluations; (4\) eyes with ischemic maculopathy and (5\) patients with foveal traction detected with OCT.

Outcomes

Primary Outcomes

Not specified

Similar Trials